Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alector, Inc.ALEC · Entity 6051 | Chief Financial Officer | June 02, 2025 | June 04, 2025 |
| Kura Oncology, Inc.KURA · Entity 4871 | CFO, CBO | January 26, 2022 | January 28, 2022 |
| Kyverna Therapeutics, Inc.KYTX · Entity 5452 | Chief Financial Officer | March 13, 2026 | March 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alector, Inc.
Report date June 02, 2025 · Filed June 04, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 296,072 |
Reported balance
After 2025-06-02 transaction · row 1
1 source rowRow 1 · 2025-06-02 · Sale · Disposed 16,488 · Balance 296,072 F1: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.285 to $1.41. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the issuer, or any security holder of the issuer upon request. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.285 to $1.41. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the issuer, or any security holder of the issuer upon request.
Kura Oncology, Inc.
Report date January 26, 2022 · Filed January 28, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,900 |
Reported balance
After 2022-01-26 transaction · row 1
1 source rowRow 1 · 2022-01-26 · Grant · Acquired 21,900 · Balance 21,900 F1: Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/23, 1/26/24, 1/26/25 and 1/26/26. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $14.15 · Expires 2032-01-25 | Direct | 131,000 |
Reported balance
After 2022-01-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-01-26 · Grant · Acquired 131,000 · Balance 131,000 F2: This option vests in 48 equal monthly installments commencing on the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/23, 1/26/24, 1/26/25 and 1/26/26.
F2: This option vests in 48 equal monthly installments commencing on the grant date.
Kyverna Therapeutics, Inc.
Report date March 13, 2026 · Filed March 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,000 |
Reported balance
After 2026-03-13 transaction · row 1
1 source rowRow 1 · 2026-03-13 · Grant · Acquired 10,000 · Balance 10,000 F1: Represents a restricted stock unit award of common stock and 1/4th of the shares underlying the restricted stock unit award shall vest on March 13, 2027 and an additional 1/4th of the shares underlying the restricted stock unit award shall vest on each one-year anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.95 · Expires 2036-03-13 | Direct | 65,000 |
Reported balance
After 2026-03-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-13 · Grant · Acquired 65,000 · Balance 65,000 F2: 1/4th of the shares subject to the option shall vest on March 13, 2027 and an additional 1/48th of the shares subject to the option shall vest on the same day of each month thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit award of common stock and 1/4th of the shares underlying the restricted stock unit award shall vest on March 13, 2027 and an additional 1/4th of the shares underlying the restricted stock unit award shall vest on each one-year anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
F2: 1/4th of the shares subject to the option shall vest on March 13, 2027 and an additional 1/48th of the shares subject to the option shall vest on the same day of each month thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 13, 2026 Filed Mar 17, 2026 16:30 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $8.95 | $0.00 |
DisclosureSEC source: 0001193125-26-110934 · ownership.xml · derivative · entry 2 GRASSO MARC · CIK 0001748894 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2036-03-13 F2 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on March 13, 2027 and an additional 1/48th of the shares subject to the option shall vest on the same day of each month thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 16:30 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-110934 · ownership.xml · nonDerivative · entry 1 GRASSO MARC · CIK 0001748894 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 F1 · shares: Represents a restricted stock unit award of common stock and 1/4th of the shares underlying the restricted stock unit award shall vest on March 13, 2027 and an additional 1/4th of the shares underlying the restricted stock unit award shall vest on each one-year anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| June 30, 2025 Filed Jul 1, 2025 20:28 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | GrantStock Option (right to buy) · Derivative | 450,000 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0000950170-25-092421 · ownership.xml · derivative · entry 1 GRASSO MARC · CIK 0001748894 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2035-06-30 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on June 30, 2026, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:21 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 16,488 | $1.34 | $22,067.54 |
DisclosureSEC source: 0001415889-25-015591 · form4-06042025_080614.xml · nonDerivative · entry 1 GRASSO MARC · CIK 0001748894 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 296,072 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.285 to $1.41. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the issuer, or any security holder of the issuer upon request. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:05 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 18,091 | $1.47 | $26,546.73 |
DisclosureSEC source: 0000950170-25-033539 · ownership.xml · nonDerivative · entry 1 GRASSO MARC · CIK 0001748894 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 312,560 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.4673 to $1.4678. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the issuer, or any security holder of the issuer upon request. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 22:40 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 16,489 | $2.52 | $41,542.39 |
DisclosureSEC source: 0000950170-24-132913 · ownership.xml · nonDerivative · entry 1 GRASSO MARC · CIK 0001748894 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 330,651 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.5193 to $2.5195. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the issuer, or any security holder of the issuer upon request. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 20:05 UTC | Alector, Inc. ALEC · Entity 6051 | GrantCommon Stock | 216,400 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-111426 · ownership.xml · nonDerivative · entry 1 GRASSO MARC · CIK 0001748894 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 347,140 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest in 12 equal quarterly installments beginning on December 1, 2024. Read SEC document |
| September 03, 2024 Filed Sep 4, 2024 20:44 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 7,297 | $4.88 | $35,620.31 |
DisclosureSEC source: 0000950170-24-103454 · ownership.xml · nonDerivative · entry 1 GRASSO MARC · CIK 0001748894 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,740 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.8815 to $4.8816. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the issuer, or any security holder of the issuer upon request. Read SEC document |
| June 03, 2024 Filed Jun 4, 2024 22:05 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 6,920 | $4.80 | $33,207.70 |
DisclosureSEC source: 0000950170-24-068937 · ownership.xml · nonDerivative · entry 1 GRASSO MARC · CIK 0001748894 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,037 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.7986 to $4.7988. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 23:00 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 5,716 | $6.92 | $39,561.58 |
DisclosureSEC source: 0000950170-24-026427 · ownership.xml · nonDerivative · entry 1 GRASSO MARC · CIK 0001748894 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,957 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.9207 to $6.9213. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 04, 2023 Filed Dec 6, 2023 23:30 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 4,574 | $5.56 | $25,431.44 |
DisclosureSEC source: 0000950170-23-068617 · ownership.xml · nonDerivative · entry 1 GRASSO MARC · CIK 0001748894 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,673 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 22:12 UTC | Alector, Inc. ALEC · Entity 6051 | GrantEmployee Stock Option (right to buy) · Derivative | 41,000 | $0.00 Strike: $6.48 | $0.00 |
DisclosureSEC source: 0000950170-23-051705 · ownership.xml · derivative · entry 2 GRASSO MARC · CIK 0001748894 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,000 Underlying: Common Stock · 41,000 shares Expires 2033-10-01 F2 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on November 1, 2023. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 22:12 UTC | Alector, Inc. ALEC · Entity 6051 | GrantCommon Stock | 123,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-051705 · ownership.xml · nonDerivative · entry 1 GRASSO MARC · CIK 0001748894 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,247 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest in 12 equal quarterly installments beginning on December 1, 2023. Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 23:14 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 1,114 | $5.19 | $5,786.45 |
DisclosureSEC source: 0000950170-23-046831 · ownership.xml · nonDerivative · entry 1 GRASSO MARC · CIK 0001748894 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,247 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. Read SEC document |
| June 02, 2023 Filed Jun 5, 2023 22:52 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 1,050 | $6.90 | $7,248.89 |
DisclosureSEC source: 0000950170-23-026477 · ownership.xml · nonDerivative · entry 1 GRASSO MARC · CIK 0001748894 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,361 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. Read SEC document |
| March 02, 2023 Filed Mar 4, 2023 01:49 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 1,291 | $8.32 | $10,739.05 |
DisclosureSEC source: 0001209191-23-016084 · doc4.xml · nonDerivative · entry 1 GRASSO MARC · CIK 0001748894 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,411 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. Read SEC document |
| October 01, 2022 Filed Oct 5, 2022 00:03 UTC | Alector, Inc. ALEC · Entity 6051 | GrantEmployee Stock Option (right to buy) · Derivative | 23,801 | $0.00 Strike: $9.46 | $0.00 |
DisclosureSEC source: 0001209191-22-052568 · doc4.xml · derivative · entry 2 GRASSO MARC · CIK 0001748894 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,801 Underlying: Common Stock · 23,801 shares Expires 2032-10-01 F2 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on November 1, 2022. Read SEC document |
| October 01, 2022 Filed Oct 5, 2022 00:03 UTC | Alector, Inc. ALEC · Entity 6051 | GrantCommon Stock | 35,702 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-052568 · doc4.xml · nonDerivative · entry 1 GRASSO MARC · CIK 0001748894 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,702 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest in 12 equal quarterly installments beginning on March 1, 2023. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:17 UTC | Alector, Inc. ALEC · Entity 6051 | GrantEmployee Stock Option (right to buy) · Derivative | 450,000 | $0.00 Strike: $15.49 | $0.00 |
DisclosureSEC source: 0001209191-22-015410 · doc4.xml · derivative · entry 1 GRASSO MARC · CIK 0001748894 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2032-03-01 F1 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on March 7, 2022. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 21:17 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 131,000 | $0.00 Strike: $14.15 | $0.00 |
DisclosureSEC source: 0001209191-22-005391 · doc4.xml · derivative · entry 2 GRASSO MARC · CIK 0001748894 · CFO, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,000 Underlying: Common Stock · 131,000 shares Expires 2032-01-25 F2 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 21:17 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantCommon Stock | 21,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005391 · doc4.xml · nonDerivative · entry 1 GRASSO MARC · CIK 0001748894 · CFO, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,900 F1 · shares: Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/23, 1/26/24, 1/26/25 and 1/26/26. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 22:20 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 175,000 | $0.00 Strike: $32.80 | $0.00 |
DisclosureSEC source: 0001209191-21-005905 · doc4.xml · derivative · entry 1 GRASSO MARC · CIK 0001748894 · CFO, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2031-01-25 F1 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| September 14, 2020 Filed Sep 15, 2020 23:23 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionOption to purchase common stock · Derivative | 2,102 | $0.00 Strike: $19.40 | $0.00 |
DisclosureSEC source: 0001209191-20-050592 · doc4.xml · derivative · entry 5 GRASSO MARC · CIK 0001748894 · CFO, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,898 Underlying: Common Stock · 2,102 shares Expires 2028-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2019. F3 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on August 21, 2018. Read SEC document |
| September 14, 2020 Filed Sep 15, 2020 23:23 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionOption to purchase common stock · Derivative | 7,898 | $0.00 Strike: $15.47 | $0.00 |
DisclosureSEC source: 0001209191-20-050592 · doc4.xml · derivative · entry 4 GRASSO MARC · CIK 0001748894 · CFO, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 7,898 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2019. F2 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on January 22, 2019. Read SEC document |
| September 14, 2020 Filed Sep 15, 2020 23:23 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 10,000 | $29.00 | $290,000.00 |
DisclosureSEC source: 0001209191-20-050592 · doc4.xml · nonDerivative · entry 3 GRASSO MARC · CIK 0001748894 · CFO, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2019. Read SEC document |
| September 14, 2020 Filed Sep 15, 2020 23:23 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionCommon Stock | 2,102 | $29.00 | $60,958.00 |
DisclosureSEC source: 0001209191-20-050592 · doc4.xml · nonDerivative · entry 2 GRASSO MARC · CIK 0001748894 · CFO, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2019. Read SEC document |
| September 14, 2020 Filed Sep 15, 2020 23:23 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionCommon Stock | 7,898 | $29.00 | $229,042.00 |
DisclosureSEC source: 0001209191-20-050592 · doc4.xml · nonDerivative · entry 1 GRASSO MARC · CIK 0001748894 · CFO, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,898 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2019. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 22:04 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionOption to purchase common stock · Derivative | 10,000 | $0.00 Strike: $15.47 | $0.00 |
DisclosureSEC source: 0001209191-20-050026 · doc4.xml · derivative · entry 3 GRASSO MARC · CIK 0001748894 · CFO, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,898 Underlying: Common Stock · 10,000 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2019. F2 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on January 22, 2019. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 22:04 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 10,000 | $26.00 | $260,000.00 |
DisclosureSEC source: 0001209191-20-050026 · doc4.xml · nonDerivative · entry 2 GRASSO MARC · CIK 0001748894 · CFO, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2019. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 22:04 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionCommon Stock | 10,000 | $15.47 | $154,700.00 |
DisclosureSEC source: 0001209191-20-050026 · doc4.xml · nonDerivative · entry 1 GRASSO MARC · CIK 0001748894 · CFO, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2019. Read SEC document |
| August 25, 2020 Filed Aug 26, 2020 22:22 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionOption to purchase common stock · Derivative | 10,000 | $0.00 Strike: $15.47 | $0.00 |
DisclosureSEC source: 0001209191-20-048436 · doc4.xml · derivative · entry 3 GRASSO MARC · CIK 0001748894 · CFO, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,898 Underlying: Common Stock · 10,000 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2019. F2 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on January 22, 2019. Read SEC document |
| August 25, 2020 Filed Aug 26, 2020 22:22 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 10,000 | $23.00 | $230,000.00 |
DisclosureSEC source: 0001209191-20-048436 · doc4.xml · nonDerivative · entry 2 GRASSO MARC · CIK 0001748894 · CFO, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2019. Read SEC document |
| August 25, 2020 Filed Aug 26, 2020 22:22 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionCommon Stock | 10,000 | $15.47 | $154,700.00 |
DisclosureSEC source: 0001209191-20-048436 · doc4.xml · nonDerivative · entry 1 GRASSO MARC · CIK 0001748894 · CFO, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2019. Read SEC document |
| August 07, 2020 Filed Aug 11, 2020 21:02 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionOption to purchase common stock · Derivative | 7,102 | $0.00 Strike: $15.47 | $0.00 |
DisclosureSEC source: 0001209191-20-046161 · doc4.xml · derivative · entry 3 GRASSO MARC · CIK 0001748894 · CFO, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,898 Underlying: Common Stock · 7,102 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2019. F3 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on January 22, 2019. Read SEC document |
| August 07, 2020 Filed Aug 11, 2020 21:02 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 10,000 | $20.00 | $200,000.00 |
DisclosureSEC source: 0001209191-20-046161 · doc4.xml · nonDerivative · entry 2 GRASSO MARC · CIK 0001748894 · CFO, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2019. Read SEC document |
| August 07, 2020 Filed Aug 11, 2020 21:02 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionCommon Stock | 7,102 | $15.47 | $109,867.94 |
DisclosureSEC source: 0001209191-20-046161 · doc4.xml · nonDerivative · entry 1 GRASSO MARC · CIK 0001748894 · CFO, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2019. F2 · balance_after: Includes 2,898 shares acquired on May 20, 2019 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| January 30, 2020 Filed Feb 3, 2020 21:07 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 111,723 | $0.00 Strike: $11.86 | $0.00 |
DisclosureSEC source: 0001209191-20-005976 · doc4.xml · derivative · entry 1 GRASSO MARC · CIK 0001748894 · CFO, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,723 Underlying: Common Stock · 111,723 shares Expires 2030-01-29 F1 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 21:08 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 140,000 | $0.00 Strike: $15.47 | $0.00 |
DisclosureSEC source: 0001209191-19-005131 · doc4.xml · derivative · entry 1 GRASSO MARC · CIK 0001748894 · CFO, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2029-01-21 F1 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| August 21, 2018 Filed Aug 22, 2018 20:12 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 250,000 | $0.00 Strike: $19.40 | $0.00 |
DisclosureSEC source: 0001209191-18-047924 · doc4.xml · derivative · entry 1 GRASSO MARC · CIK 0001748894 · CFO, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2028-08-20 F1 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.